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Cytokine levelsIntroduction: Preeclampsia (PE) is a multi-system disorder of pregnancy characterized by hypertension
and proteinuria. Healthy pregnancy is associated with a controlled inﬂammatory process, which is exac-
erbated in PE in response to excessive placental stimuli. Gene expression levels can affect inﬂammation
and immune regulation. It is known that differences in cytokine allele frequencies amongst populations
may contribute to difference in the incidence of several diseases.
Objective: The aim of this study was to investigate the frequency of TNF-a, IL-6, IFN-c and IL-10 genes
polymorphisms and their relationship with the cytokines plasma levels in PE.
Methods: A total of 281 women were included in this study; 116 with severe PE, 107 normotensive preg-
nant and 58 non-pregnant women. Cytokine genotyping was carried out by the polymerase chain reac-
tion. The analyzed polymorphisms were: TNF-a (308 G? A), IL-10 (1082 G? A), IL-6 (174 G? C),
and IFN-c (+874 A? T). Cytokine plasma levels were measured by Cytometric Bead Array method.
Results: A higher frequency of the IFN-c (+874) T/T genotype in severe PE comparing to normotensive
pregnant women was found (P < 0.001). TNF-a, IL-6 and IFN-c plasma levels were higher in PE women
compared to non-pregnant women (P < 0.001; P < 0.001; P = 0.004). IL-6 and IFN-c levels were also higher
in PE women compared to normotensive pregnant (P < 0.001; P = 0.010). IL-10 levels were higher in nor-
motensive pregnant women compared to PE (P < 0.001). IFN-c and IL-6 genes polymorphisms inﬂuenced
the genic expression in PE and normotensive pregnant women, respectively.
Conclusions: These results suggest that IFN-c seems to play a role in PE occurrence.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Preeclampsia (PE) is a multifactorial disease characterized by
systolic blood pressure P140 mmHg or diastolic P90 mmHg at
bed rest, on at least two occasions, six hours apart, and proteinuria
P0.3 g/24 h, measured after the 20th week of pregnancy [1].
Symptoms frequently observed in PE include headache, blurred
vision, and abdominal pain. The etiology of PE is unknown and
the delivery of placenta remains the only known treatment.
Clinically, it is important to diagnose the severe form of PE when
hypertension and proteinuria are even higher. This disease canprogress to eclampsia (characterized by seizures as a sign of affec-
tion of the cerebral vessels), syndrome HELLP (hemolysis, elevated
liver enzyme, low platelets) or disseminated intravascular coagula-
tion [2]. PE is associated with placental disorder, endothelial cell
dysfunction and systemic vasospasm. The events leading to these
alterations remain unclear, but it seems that abnormal immune
system activation plays a relevant role in PE development [2,3].
Healthy pregnancy is associated with a controlled inﬂammatory
process, which is exacerbated in PE in response to excessive placen-
tal stimuli [4]. Previous studies suggested that cytokines might be
involved in the PE pathogenesis. High levels of interleukin (IL)
IL-1, IL-6 and tumor necrosis factor alpha (TNF-a), as well as IL-2
and interferon gamma (IFN-c), have been detected in plasma and
amniotic ﬂuid of PE women. All these inﬂammatory cytokines seem
to have deleterious effects on pregnancy development [5–7]. IL-10
has been identiﬁed as an important cytokine in successful
Table 1
Clinical characteristics of participants.
Characteristics Control group Preeclamptic women P value
Age (years) 25.8 (6.22) 26.8 (7.16) 0.207
GA (weeks) 32.9 (4.68)a 33.0 (4.04) 0.799
GWG (kg) 10.0 (6.75–13.55)a 12.7 (8.50–16.50) 0.002*
BMI (kg/m2) 23.25 (20.53–26.90) 23.98 (21.63–28.13) 0.128
SBP (mmHg) 110 (100.0–120.0) 170 (160.0–180.0) <0.001*
DBP (mmHg) 70 (70.0–80.0) 110 (100.0–120.0) <0.001*
GA: gestational age; GWG: gestational weight gain; SBP: systolic blood pressure;
DBP: diastolic blood pressure; BMI: body mass index.
Age and GA are presented as mean (standard deviation). Student t test.
GWG, BMI, SBP and DBP are presented as median (25th–75th centiles). Mann–
Whitney test.
a Only normotensive pregnant.
* p < 0.05 – Statistic signiﬁcant.
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tion in PE may cause a pro-inﬂammatory cytokine maternal
response, resulting in pregnancy complications [6,9,10].
It has been reported that phytohemagglutinin (PHA)-stimulated
IFN-c production in peripheral blood mononuclear cells (PBMC) in
PE women is signiﬁcantly higher compared to normotensive preg-
nant women [6,11–14]. Elevated IFN-c levels in pregnancy can be
potentially harmful to the fetus. It is known that IFN-c inhibits the
outgrowth of trophoblast cells in vitro [15] and synergistically
stimulates the programmed death of primary villous trophoblast
cells [16,17].
Point mutations and single nucleotide substitutions (SNPs) in
the regulatory regions of cytokine genes may affect cytokine tran-
scription and inﬂuence its production.
The relationship between PE and SNPs in cytokine genes has
been investigated, but remains unclear [18–31]. Therefore, the
aim of this study was to investigate whether the TNF-a (308
G? A), IL-6 (174 G? C), IFN-c intron 1 (+874 A? T) and IL-10
(1082 G? A) genes polymorphisms are associated with severe
PE occurrence.
2. Subjects and methods
2.1. Ethical aspects
This study was approved by the Ethics Committee of Federal
University of Minas Gerais-Brazil and informed consent was
obtained from all participants. The research protocol did not inter-
fere with any medical recommendations or prescriptions.
2.2. Study design
The present case-control study included 281 women; 116 with
severe PE, 107 normotensive pregnant and 58 non-pregnant
women, selected from Odete Valadares Maternity-Belo Horizonte,
Brazil, Regional Public Hospital of Betim, Brazil and Healthy Center
Guanabara, Betim, Brazil from 2008 to 2011.
2.3. Inclusion criteria
Severe PE was deﬁned by systolic blood pressure P160 mmHg
or diastolic blood pressureP110 mmHg, presented in two consec-
utive occasions at bed rest at least four hours apart; and proteinuria
>2 gL–1/24 h or at least 2+ protein by dipstick. Normotensive preg-
nant women had systolic/diastolic blood pressure below 120/
80 mmHg and no history of hypertension or proteinuria. All preg-
nant women showed gestational age P20 weeks. Non-pregnant
women had no clinical and laboratory alterations, including
hypertension.
2.4. Exclusion criteria
Exclusion criteria common for the three groups were chronic
hypertension, haemostatic abnormalities, cancer, diabetes melli-
tus, cardiovascular, autoimmune, renal and hepatic diseases, and
anticoagulant therapy.
2.5. Cytokine gene polymorphism analysis
DNA was extracted and puriﬁed from whole blood, collected in
EDTA using Biopur Mini Spin Kit (Biometrix, Brazil).
Cytokine genotyping was carried out by the polymerase chain
reaction (PCR) sequence-speciﬁc primer method, using the ‘Cyto-
kine Genotyping Tray’ (One Lambda Inc., Canoga Park, CA, USA).
The kit accuracy was checked by our laboratory using knownDNA samples. The PCR products were then visualized by electro-
phoresis in 2% agarose gel stained with ethidium bromide and doc-
umented with a Polaroid camera. The polymorphisms analyzed in
the present study were: TNF-a (308 G? A), IL-10 (1082
G? A), IL-6 (174 G? C), and IFN-c (+874 A? T).
The cytokine genotypes were grouped according to the ﬁnal
phenotype on gene expression. For the TNF-a gene, the genotypes
were distributed as A/A and A/G (high) and G/G (low); for the IL-10
gene, the genotypes were distributed as G/G (high), G/A (interme-
diate) and A/A (low); for the IL-6 gene, the genotypes were distrib-
uted as G/G and G/C (high) and C/C (low); and for the IFN-c gene,
the genotypes were distributed as T/T (high), T/A (intermediate)
and A/A (low) [32–35].
2.6. Determination of cytokine plasma levels
Samples collected in EDTA were centrifuged at 2500g for 20 min
at 4 C to obtain plasma, which was stored at 80 C until analysis.
Data acquisition and analysis were performed in dual-laser FAC-
Scalibur™ ﬂow cytometer (BD Biosciences Pharmingen, San Jose,
CA, USA), using the BD Bioscience CBA software. IFN-c was deter-
mined using the Human Th1/Th2 Cytometric Bead Array method
(BD Biosciences Pharmingen, USA). IL-6, IL-10 and TNF-a were
determined using Human Inﬂammation Kit (BD Biosciences
Pharmingen, USA), according to the manufacturers’ instructions.
Results were expressed as mean ﬂuorescence intensity (MFI) for
each cytokine.
2.7. Statistical analysis
Statistical analysis was carried out using SPSS (version 13.0)
and GENEPOP software. Hardy–Weinberg equilibrium was investi-
gated through probability test. Data normality was tested by Shap-
iro–Wilk test. Comparisons between two groups were made by
Student t test for parametric variables and Mann–Whitney for
non-parametric variables. A comparison of non-parametric vari-
ables was done by Kruskal–Wallis test amongst three groups.
When differences were detected among groups, these were com-
pared in pairs by Mann–Whitney method, followed by Bonferroni
test. The comparison of categorical variables was performed using
the chi-square test (v2). When P < 0.05, residue adjusted analysis
was made to identify where was the difference. Spearman’s corre-
lations were computed to assess correlations with cytokine plasma
levels and cytokine genotype. P values <0.05 were considered sta-
tistically signiﬁcant.
3. Results
Table 1 summarizes the clinical characteristics of the 281
women enrolled in this study. PE women, normotensive pregnant
234 M.B. Pinheiro et al. / Cytokine 71 (2015) 232–237and non-pregnant women showed similar ages (P = 0.207) and
body mass index (BMI) (P = 0.128). Normotensive pregnant and
PE women did not show differences regarding gestational age
(P = 0.799). As expected, systolic and diastolic blood pressures
were signiﬁcantly higher in PE women, comparing to the other
two groups (P < 0.001, in both of cases), as well as the gestational
weight gain, when compared to normotensive pregnant women
(P = 0.002).
The case (PE) and control group (normotensive pregnant and
non-pregnant women) were under Hardy–Weinberg equilibrium
(P = 0.289 and P = 0.364, respectively.)
Phenotyping data are presented in Table 2. A higher frequency
of the IFN-c (+874) T/T genotype in PE women compared to nor-
motensive pregnant group was observed (PE women: T/T 28%
and A/A 28%; normotensive pregnant: T/T 5% and A/A 58%,
P < 0.001). However, no differences between cases and controls
were found in phenotypes distribution for TNF-a (308), IL-10
(1082) and IL-6 (174) polymorphisms.
Cytokine plasma levels were analyzed as mean ﬂuorescent
intensity (MFI) provided by CBA immunoassay (Fig. 1). To assess
whether pregnancy is able to induce different levels of cytokines,
this analysis was performed separately in each studied group.
TNF-a, IL-6 and IFN-c plasma levels were higher in PE women
compared to non-pregnant women (P < 0.001; P < 0.001;
P = 0.004, respectively). Furthermore, IL-6 and IFN-c levels were
also higher in PE women compared to normotensive pregnant
women (P < 0.001; P = 0.010, respectively). However, IL-10 levels
were higher in normotensive pregnant compared to PE women
(P < 0.001) and non-pregnant women (P < 0.001). Aiming to evalu-
ate whether the polymorphisms in TNF-a, IL-10, IL-6 and IFN-c
genes inﬂuence the genic expression, plasma levels of these cyto-
kines were compared to phenotypes determined by genotypes
(Table 3). Increased levels of IL-6 in ‘‘high’’ phenotype compared
to ‘‘low’’ phenotype (P = 0.05) were observed in normotensive
pregnant women. Furthermore, increased levels of IFN-c in ‘‘high’’
compared to ‘‘intermediate’’ (P = 0.012) and ‘‘low’’ phenotypes
(P < 0.001) were found in PE women.
In order to investigate the correlation between genotypes and
cytokines plasma levels, the three groups were analyzed together.
A signiﬁcant positive correlation between IFN-c plasma levels and
the presence of +874T allele was observed (P < 0.001, r = 0.302).
When the three groups were evaluated separately, a signiﬁcant
positive correlation between IL-6 levels and 174C allele
(P = 0.05, r = 0.236) in normotensive pregnant women wasTable 2
Phenotype frequencies of TNF-a, IL-10, IL-6 and IFN-c polymorphisms in women with pre
Polymorphisms genotypes (phenotypea) Non-pregnant (N = 58)
TNF-a (308 G? A)
A/A; A/G (high) 16 (0.28)
G/G (low) 42 (0.72)
IL-10 (1082 G? A)
G/G (high) 7 (0.12)
G/A (intermediate) 25 (0.43)
A/A (low) 26 (0.45)
IL-6 (174 G? C)
G/G; G/C (high) 55 (0.95)
C/C (low) 3 (0.05)
IFN-c (+874 A? T)
T/T (high) 6 (0.10)
T/A (intermediate) 19 (0.33)
A/A (low) 33 (0.57)
Values in parentheses are frequency.
a Cytokine production phenotype according to the Hoffmann et al. [46], Pravica et al.
* P < 0.05.
** <1.96, less frequent.
*** >1.96, more frequent (analysis of adjusted residual).evidenced. Moreover, in PE women, it was found a signiﬁcant posi-
tive correlation between IFN-c plasma levels and +874T allele
(P = 0.004, r = 0.372). The other polymorphisms did not show cor-
relation with cytokines levels.4. Discussion
In the present study, the +874 T/T genotype in IFN-c gene was
more frequent in PE women than in the control group (normoten-
sive pregnant and non-pregnant women). Therefore, given the
decisive role of IFN-c in pregnancy (and the presence of functional
polymorphisms in the ﬁrst intron of the IFN-c gene), our data sug-
gest that this gene might plausibly be a candidate for susceptibility
gene in PE. In contrast, a study involving Brazilian preeclamptic
and eclamptic women showed higher frequency of IFN-c + 874 A
in eclamptic women compared to controls [21]. The authors admit-
ted that these results were unexpected and could have occurred by
chance, since they did not detect a corresponding expression in
genotype frequency. However, other studies have investigated this
polymorphism in PE women and did not ﬁnd association between
genotypes or allele frequencies of IFN-c gene and this disease
[19,24]. These conﬂicting ﬁndings could have resulted from the
heterogeneity in study designs, deﬁnition of phenotype, population
diversity and sample size. Our study evaluated a huge sample size
in a clinical homogeneous group, since only severe PE cases were
investigated. Therefore, this result suggests that +874 T/T genotype
in IFN-c gene is associated with severe PE in the studied
population.
No association between TNF-a (308 G? A), IL-6 (174
G? C), or IL-10 (1082 G? A) polymorphisms and PE was
observed. These results are in line with other publications
[18,19,21,22,24,28,29,31,36–43] and in disagreement with others
[19,23–27,31]. A reason for discrepant results among different
studies might be the selection bias and small sample size in retro-
spective studies, or ethnic differences in the studied populations.
There are several lines of evidences suggesting that IL-10 has an
important role in pregnancy. IL-10 has a critical function in differ-
ent obstetric pathologies associated to down regulation of inﬂam-
matory responses in the placenta [44]. PE has also been associated
with a deﬁciency of placental IL-10, which induces T lymphocytes
to differentiate along the Th2 pathway and block IFN-c production.
It is known that IFN-c is the major Th1 lymphocyte product that
induces pro-inﬂammatory cytokine synthesis [44]. Mirhamadian
et al. [26] found signiﬁcantly higher C/C genotype frequency ofeclampsia (PE) and the control groups.
Normotensive pregnant (N = 107) PE (N = 116) P
0.781
30 (0.28) 28 (0.24)
77 (0.72) 88 (0.76)
0.785
9 (0.08) 11 (0.09)
53 (0.50) 61 (0.53)
45 (0.42) 44 (0.38)
0.258
104 (0.97) 107 (0.92)
3 (0.03) 9 (0.08)
<0.001*
5 (0.05)** 33 (0.28)***
40 (0.37) 51 (0.44)
62 (0.58)*** 32 (0.28)**
[47], Turner et al. [48], and Wilson et al. [49]. Pearson chi-square test.
Fig. 1. Cytokine plasma levels in preeclamptic women ( ) as compared to normotensive pregnant women ( ) and non-pregnant women ( ). Plasma levels of cytokines
were determined by cytometric beads array. Results are expressed in mean ﬂuorescence intensity (MIF) data are presented in a box plot format. The lines stretch from the
10th percentile to the upper 90th percentile, highlighting the outliers (d). The median is shown as a line across the box. Statistical analysis was performed by non-parametric
Mann–Whitney test. Signiﬁcant differences at P < 0.05 are highlighted by connecting lines. ⁄non-pregnant X PE; ⁄⁄normotensive X PE; ⁄⁄⁄non-pregnant X normotensive.
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agreement with other studies [20–22,30] our data did not show
association between PE and IL-10 gene polymorphism. Accord-
ingly, a recent meta-analysis showed no association between PE
and IL-10 polymorphisms (1082 G? A) [43].
IL-6 is a critical cytokine in the cascade of host response to
infection. IL-6 activates the acute phase response, stimulates T
lymphocytes, induces the terminal differentiation of B-lympho-
cytes, and induces C reactive protein production [45]. It has
recently been reported that in PE, endothelial cells phagocytes kill
trophoblasts shedding from placenta to maternal blood. Phagocy-
tosis of necrotic trophoblasts cause endothelial cells activation
and subsequent IL-6 release [46,47]. Several studies have been
reporting increased IL-6 levels in PE [43,48–52].
It is known that the IL-6 production is under genetic regulation.
A polymorphism in the promoter region of IL-6 (174 G? C) gene,
on chromosome 7 [53] is associated with the production of IL-6
[32]. The C/C genotype of this polymorphism is related to reduced
IL-6 production, whereas homozygous G/G or heterozygous G/C
displays normal production. In agreement with our results, other
studies did not ﬁnd an association between polymorphism in IL-6
gene promoter (174 G? C) and PE occurrence [19,21,28,29,42],
which was conﬁrmed by a recent metanalysis [43].
TNF-a is a potent and multi-functional cytokine produced by
macrophages, lymphocytes and trophoblast. It contributes to the
abnormal placental invasion [54], endothelial cell damage [55]and oxidative stress [56]. An excessive inﬂammatory response to
pregnancy seems to characterize PE, and TNF-a represents a major
mediator of this reaction [38]. Our data did not show any associa-
tion between polymorphism in TNF-a gene and PE occurrence or
TNF-a plasma levels. In agreement with our data, two metanalysis
[36,43] revealed no association between polymorphism 308
G? A and PE. Nonetheless, in one of these metanalysis [43] it
was found an association between high TNF-a plasma levels and
PE. In accordance, our data showed high TNF-a plasma levels in
PE comparing to non-pregnant women, which could suggest that
this cytokine may have a role in PE.
Our data showed increased inﬂammatory cytokines levels, IL-6
and IFN-c, in PE women comparing to normotensive pregnant
women. Supporting our ﬁndings, some studies have demonstrated
an increase in IFN-c [48–51,57] and IL-6 in PE [43,48–52], which
was conﬁrmed by a recent metanalysis [43]. However, we found
decreased levels of the regulatory cytokine IL-10. It has been sug-
gested that decreased IL-10 production in PE may cause a pro-
inﬂammatory cytokine response.
As IL-10 has a very short half-life, it is not consistently present
in the circulation. Thus, a single blood sample may fail to detect a
sporadic elevation or reduction in this cytokine level. Different fac-
tors, such as the effect of gestational age at the time of blood sam-
ple collection, the inﬂuence of body mass index and the assay
sensitivity to measure IL-10 may also explain the divergences in
results found in the studies [19].
Table 3
Evaluation of polymorphism inﬂuence in circulating levels of cytokines.
Population Cytokines Polymorphism Genotype (phenotypea) P value
High Intermediate Low
Non-pregnant TNF-a 4.00 (3.80–4.20) NA 3.90 (3.20–4.10) 0.812
IL-10 4.75 (3.80–5.70) 4.00 (3.70–4.90) 4.55 (3.80–5.70) 0.515
IL-6 7.71 (5.73–18.60) NA – –
IFN- c 3.32 (2.00–4.91) 3.53 (2.09–4.01) 2.83 (1.33–3.96) 0.183
Normotensive pregnant TNF-a 4.00 (3.80–4.70) NA 3.90 (3.50–4.70) 0.585
IL-10 8.20 (6.00–9.60) 8.65 (4.50–13.20) 8.25 (6.50–11.10) 0.456
IL-6 8.82 (3.90–14.86) NA 6.66 (6.21–7.10) 0.050⁄
IFN-c 4.2 (3.79–4.61) 3.54 (2.76–4.33) 3.53 (2.23–4.61) 0.390
Preeclamptic women TNF-a 4.10 (4.20–6.00) NA 4.10 (4.50–6.80) 0.637
IL-10 4.55 (3.70–5.30) 5.20 (4.20–6.80) 4.15 (3.30–5.90) 0.155
IL-6 12.92 (4.57–176.24) NA 19.99 (9.73–75.67) 0.187
IFN- c 4.45 (3.18–5.73) 3.79 (2.67–4.41) 3.89 (2.62–4.83) 0.012b⁄
<0.001c⁄
0.494d
Levels of plasma cytokine measured by median ﬂuorescence intensities (MFI); NA, Not applicable; (–) no woman had the phenotype ‘‘low’’ (C/C). Data were compared by the
Kruskal–Wallis and Mann–Whitney test. Values are presented as median (25th–75th centiles).
a Cytokine production phenotype according to the Hoffmann et al. [46], Pravica et al. [47] Turner et al. [48], and Wilson et al. [49]. b. High  Intermediate; c. High  low; d.
Intermediate  low.
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‘‘high’’ phenotype compared to ‘‘intermediate’’ and ‘‘low’’ pheno-
types. This ﬁnding suggests that pregnancy is able to increase IL-
6 levels and this cytokine may be important to physiologic gesta-
tional development. However, it is known that IL-6 levels depend
on the genotype that determines the ‘‘high’’ phenotype. Some cyto-
kines such as IL-4, IL-6 and IL-10 seem to favor pregnancy success
whereas others such as TNF-a and IFN-c are harmful. In pregnancy,
there is a greater increase in IL-6 production compared to the non-
pregnant state [58]. IL-6 may induce prostaglandin synthesis by
intrauterine tissues, suggesting its physiological role in labor.
Moreover, IL-6 is considered a Th2 cytokine, but it may perform
‘‘Th1-type’’ or ‘‘Th2-type’’ functions depending on the biological
condition [7]. However, several studies showed that IL-6 plasma
levels are higher in women presenting pregnancy complications,
when compared to healthy pregnant women, which suggests a role
for this cytokine in these disturbances [43,48–52,59].
To the best of our knowledge, this is the ﬁrst study investigating
the relationship between IFN-c levels and gene polymorphism inFig. 2. Cytokine levels and genotype associated to favorable and unfavorable PE
occurrence.PE. Our data revealed increased IFN-c plasma levels in preeclamp-
tic women with ‘‘high’’ phenotype compared to ‘‘intermediate’’ and
‘‘low’’ phenotypes. Besides, a positive correlation between IL-6 lev-
els and ‘‘high’’ phenotype in normotensive pregnant women was
revealed. Moreover, this association was also observed evaluating
the three groups together. These results point to the importance
of IL-6 production in healthy pregnancy. On the other hand, IFN-
c seems to play an essential role in PE occurrence (Fig. 2).5. Conclusion
Our results suggest that IFN-c seems to play a role in PE
occurrence.
The inﬂammatory markers results will certainly reﬂect such dif-
ferences, leading to controversial research conclusions. Moreover,
maternal and fetal genes interacting with each other (and a variety
of environmental stimuli) interfere on the PE severity and
outcome. Based on these considerations, further studies are
undoubtedly needed in order to clarify the association of genes
polymorphisms and maternal cytokines production. In this sense,
reproducing our ﬁndings in other populations will help deﬁning
the inﬂuence of genes polymorphisms and cytokine production
in PE pathophysiology.Acknowledgements
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